Original language | English (US) |
---|---|
Pages (from-to) | 1024-1026 |
Number of pages | 3 |
Journal | Clinical Journal of the American Society of Nephrology |
Volume | 15 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2020 |
ASJC Scopus subject areas
- Epidemiology
- Critical Care and Intensive Care Medicine
- Nephrology
- Transplantation
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Clinical Journal of the American Society of Nephrology, Vol. 15, No. 7, 07.2020, p. 1024-1026.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - The feasibility and safety of obtaining research kidney biopsy cores in patients with diabetes an interim analysis of the trident study
AU - TRIDENT Study Investigators
AU - Hogan, Jonathan J.
AU - Owen, Jonathan G.
AU - Blady, Shira J.
AU - Almaani, Salem
AU - Avasare, Rupali S.
AU - Bansal, Shweta
AU - Lenz, Oliver
AU - Luciano, Randy L.
AU - Parikh, Samir V.
AU - Ross, Michael J.
AU - Sharma, Deep
AU - Szerlip, Harold
AU - Wadhwani, Shikha
AU - Townsend, Raymond R.
AU - Palmer, Matthew B.
AU - Susztak, Katalin
AU - Mottl, Amy K.
N1 - Funding Information: Dr. S. Almaani reports personal fees from Aurinia, outside the submitted work. Ms. S.J. Blady reports other from University of Pennsylvania, during the conduct of the study. Dr. J.J. Hogan reports grantsfromBoehringerIngelheim,GileadSciences,GlaxoSmithKline and Regeneron Pharmaceuticals, during the conduct of the study; personal fees from Retrophin, personal fees from Dimerix, personal fees from Zyversa, personal fees from GSK, other from Calliditas, other from Omeros, other from Achillion, outside the submitted work. Dr. A.K. Mottl received other funding from Duke Clinical Research Institute, Pfizer, Aurinia, and Calliditas, outside the submitted work. Dr. S.V. Parikh reports personal fees from AstraZeneca, Aurinia Pharmaceuticals, and Bristol Myers Squib, and grants from Funding Information: the NIH, outside the submitted work, and grants from Aurinia Pharmaceuticals, EMD-Serono, and Mallinckrodt, outside the submitted work. Dr. S. Wadhwani reports personal fees from Bristol-Myers Squibb, Alexion Pharmaceuticals, and the Lupus Foundation of America, and grants from the NIH, outside the submitted work. Dr. K. Susztak reports personal fees from Janssen, Novo Nordisk, Maze, and Jnana Therapeutics, Boerhinger Ingelheim Japan, Kiowa Kirin. Dr. O. Lenz reports that he is president and majority shareholder of L & F Health LLC, outside of submitted work. Dr. D. Sharma reports grant funding from GlaxoSmithKlein, outside the submitted work. Dr. H. Szerlip reports personal fees from AstraZeneca, Retrophin, Lajolla and Janssen, outside the submitted work, grants from University of Pennsylvania, during the conduct of the study, and grants from Retrophin, Aurinia, Omeros, Bayer, Akebia, AstraZeneca, outside the submitted work. All remaining authors have nothing to disclose. Funding Information: The Transforming Research in Diabetic Nephropathy study is supported by Boehringer Ingelheim, GlaxoSmithKline, Regeneron Pharmaceuticals, and Gilead Sciences, Inc.
PY - 2020/7
Y1 - 2020/7
UR - http://www.scopus.com/inward/record.url?scp=85087552504&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087552504&partnerID=8YFLogxK
U2 - 10.2215/CJN.13061019
DO - 10.2215/CJN.13061019
M3 - Letter
C2 - 32341009
AN - SCOPUS:85087552504
SN - 1555-9041
VL - 15
SP - 1024
EP - 1026
JO - Clinical Journal of the American Society of Nephrology
JF - Clinical Journal of the American Society of Nephrology
IS - 7
ER -